Regulatory Aspects of Pharmaceuticals’ Exports in Gulf Cooperation Council Countries
2011

Regulatory Aspects of Pharmaceuticals’ Exports in Gulf Cooperation Council Countries

Sample size: 215 publication Evidence: moderate

Author Information

Author(s): Pateriya S Janodia, Deshpande PB, Ligade VS, Talole KB, Kulshrestha T, Kamariya Y, Musmade PB, Udupa N

Primary Institution: Manipal University

Hypothesis

The understanding of the regulatory requirements of the Gulf Cooperation Council (GCC) region can enhance pharmaceutical exports from India.

Conclusion

The GCC market presents significant opportunities for the Indian pharmaceutical industry as traditional markets become saturated.

Supporting Evidence

  • The Indian pharmaceutical industry has seen a growth of 29% in exports for the year 2008-09.
  • Exports to the US have declined by 36.8%, prompting a search for new markets.
  • The GCC countries have a high demand for pharmaceuticals, with 80% of their needs met through imports.

Takeaway

This study shows that Indian drug manufacturers can benefit from exporting to Gulf countries, which are looking for quality generic products.

Methodology

The study is based on responses from representatives of leading pharmaceutical manufacturers in India and those registered in the six GCC countries.

Participant Demographics

Representatives from leading pharmaceutical manufacturers in India and GCC countries.

Digital Object Identifier (DOI)

10.4103/0975-1483.80305

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication